Introduction:

Lymphadenectomy is the method of choice in lymphatic evaluation in patients diagnosed with prostate cancer. The first challenge is to know the probability of involvement with nomograms, Partin, being the most used. According to these nomograms, those patients with node involvement higher than 2% have an indication for lymphadenectomy during prostatectomy for therapeutic and prognostic purposes. Biochemical recurrence is defined as a serum prostate-specific antigen level greater than 0.2 ng / ml confirmed at least 4 weeks after prostatectomy.

Material and methods:

We performed an observational retrospective study where the records of 150 consecutive radical prostatectomy cases performed between 2007-2019 were reviewed. A total of 109 patients were included. The probability of lymph node involvement was calculated by Partin nomogram, and all those with more than 2% were selected. They were divided into two groups: with pelvic lymph node dissection (PLND group) or without pelvic lymph node dissection (non-PLND). A Shapiro-Wilks analysis was carried out to check the normality of the data. The p <0.01 in both cases, therefore a Wilcoxon test was carried out, using the Statistical 8.0 program

Results:

Using a Spearman correlation and with a p> 0.01, it was found that there was no relationship between the calculation of more than 2% of lymph node involvement by Partin and early biochemical recurrence. We found no significant differences.

Conclusion:

In our study, lymphadenectomy did not showed difference in the risk of biochemical progression. Sparing pelvic lymphadenectomy during prostatectomy with a percentage greater than or equal to 2% per Partin nomogram does not have a direct relationship with biochemical recurrence. The use of other nomograms adjusted to our population can make a difference in these results.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )